

July 30, 2019

Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research (NOT-OD-19-126)

The National Institutes of Health (NIH) issued a notice to inform the extramural research community of upcoming HHS requirements and review considerations regarding research that is supported by the NIH and involves the proposed use of human fetal tissue obtained from elective abortions (HFT) in extramural applications for grants, cooperative agreements and R&D contracts. These requirements are in addition to the existing requirements as detailed in the NIH Grants Policy Statement (4.1.14). In addition, NIH reminds the community of expectations to obtain informed consent from the donor for any NIH-funded research using HFT (NOT-OD-16-033).

Applicability

The changes outlined in this notice will apply to competitive applications for grants and cooperative agreements submitted for due dates on or after September 25, 2019 and R&D contract proposals submitted to solicitations issued after September 25, 2019.

This notice does not address any changes to Research Performance Progress Reports (RPPR) for currently active grant awards or annual progress reports for ongoing contract awards with respect to research including HFT.

For competing grant applications submitted for due dates on or after September 25, 2019 and R&D contract solicitations published on or after September 25, 2019, NIH will require applicants/contract offerors to address HFT requirements. Applicants must provide a justification of the use of HFT, details regarding procurement and costs, and information about how the applicant/contract offeror will use HFT. These additional requirements must be met within existing applicable page limits.

Applications that do not address all of the required information, including the detailed budget as instructed, will be administratively withdrawn and not reviewed.

Read the full notice here.

